You just read:

Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment

News provided by

Lightlake Therapeutics Inc.

Dec 03, 2013, 04:05 ET